The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules
The company has posted net profit of Rs. 30.53 crores for the Financial Year ended March 31, 2025
The inspection conducted from December 16, 2024 to December 20, 2024 by the Brazil Health Regulatory Agency (ANVISA)
The implementation, spearheaded by Deloitte Consulting, brings together domain expertise and cutting-edge technology
The company will receive GMP compliance certificate which will further help to accelerate the business growth across the globe
Wanbury receives CEP approval from EDQM for launch of Dextromethorphan API
These accolades highlight our unwavering commitment to maintaining the highest safety standards
Patni brings over 25 years of distinguished experience in the pharmaceutical industry
He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years
Subscribe To Our Newsletter & Stay Updated
